| Ticker |
MBOT
|
| CIK | 0000883975 |
| SIC | 3841 |
| Sector | Manufacturing |
| Industry Category | Medical Equipment |
| Industry Group | Surgical, Medical, And Dental Instruments And Supplies |
| Address | 25 RECREATION PARK DR SUITE 108, HINGHAM, MA, 02043 |
| Website | www.microbotmedical.com |
| Phone | 908-938-5561 |
| CEO | Harel Gadot |
| Employees | 20 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Microbot Medical Secures China Patent for LIBERTY System, Eyes Q3 2025 US LaunchMicrobot Medical Inc. (NASDAQ:MBOT) is one of the best-performing NASDAQ stocks according to analysts. On June 17, Microbot Medical announced that it had been granted a patent in China by the China National Intellectual Property Administration/CNIPA. The patent covers the robotic manipulation of a surgical tool handle and is a step in the company’s global […] Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual MeetingLeading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the SpecialtyHINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, being held from July 16-20, in Strasbourg, France. The Company applauds the SRS for recognizing the growing need to spotl Microbot Medical® Added to the Russell Microcap® IndexAutomatic inclusion in the appropriate growth and value style indexesHINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition will be effective today when the U.S. equity markets open. “Inclusion in the Russell Microcap® Index marks another important milestone for Microbot Medical. It reflects the stro Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, Microbot... Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in ChinaSignificant Development Supports Long-Term Global Commercial Strategy of the LIBERTY® SystemHINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA), a key step in the Company’s global IP expansion strategy. The patent, which covers the robotic manipulation of a surgical too |
